Physician profile
David Barron
NPI 1235491440
$9,872.41
in general payments reported to CMS, 2019-2025
12 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2022: $100 · 2023: $273 · 2024: $8,622 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,600 · Food and Beverage: $1,578 · Travel and Lodging: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,600.00 |
| Food and Beverage | $1,577.57 |
| Travel and Lodging | $1,352.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,614.02 | 2022-2025 | Spaceoar System, Spaceoar Vue System - 10ml |
| Sirtex Medical INC | $261.47 | 2019-2024 | Sir-Spheres Microspheres |
| Stryker Corporation | $251.72 | 2023 | Iconix |
| Medtronic, INC. | $151.18 | 2025 | Inceptiv |
| Elekta, INC. | $151.00 | 2025 | |
| Histosonics, INC. | $150.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $103.30 | 2024 | Libtayo |
| Foundation Medicine, INC. | $98.48 | 2019 | |
| Progenics Pharmaceuticals, INC. | $44.08 | 2022-2023 | Pylarify |
| Monteris Medical Corporation | $32.54 | 2024 | Neuroblate |
| Novocure INC. | $14.62 | 2025 | Optune Lua (Novottf-200t) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,791.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.